Saturday, Feb 4, 2023
English News
  • Hyderabad
  • Telangana
  • Andhra Pradesh
  • India
  • World
  • Entertainment
  • Science and Tech
  • Sport
  • Business
  • ...
    • NRI
    • View Point
    • cartoon
    • Columns
    • Reviews
    • Education Today
    • Property
    • Videos
    • Lifestyle
    • Rewind
E-Paper
  • NRI
  • View Point
  • cartoon
  • Columns
  • Reviews
  • Education Today
  • Property
  • Videos
  • Lifestyle
  • Rewind
Home | India | Bharat Biotech Seeks Dcgis Nod To Conduct Nasal Covid Vaccine Trials

Bharat Biotech seeks DCGI’s nod to conduct nasal Covid vaccine trials

The nasal vaccine is different from the two intramuscular vaccines which recently got approval, due to being non-invasive, needle-free, not requiring trained healthcare workers, eliminating needle-associated risks, and suitable for children and adults, having scalable manufacturing.

By IANS
Published Date - 06:05 PM, Fri - 8 January 21
Bharat Biotech seeks DCGI’s nod to conduct nasal Covid vaccine trials

New Delhi: Days after getting Drugs Controller General of India’s (DCGI) nod for India’s first indigenously-made coronavirus vaccine, Bharat Biotech has again knocked on the doors of the drug controller seeking permission to conduct clinical trials of their intranasal vaccine for the viral disease.

Hyderabad-based Bharat Biotech has applied to the DCGI for permission to start Phase 1 and 2 trials of their nasal coronavirus vaccine, top sources privy to the development told IANS.

Clinical trials of the ‘BBV154’ – a novel adenovirus vectored, intranasal vaccine for coronavirus — will be conducted at various locations. The vaccine will be a single-dose one.

The nasal vaccine is different from the two intramuscular vaccines which recently got approval, due to being non-invasive, needle-free, not requiring trained healthcare workers, eliminating needle-associated risks, and suitable for children and adults, having scalable manufacturing.

According to the firm, an intranasal vaccine stimulates a broad immune response at the site of infection, in the nasal mucosa, which is essential for blocking both infection and transmission of Covid-19.

The vaccine has demonstrated protective efficacy in mice and hamsters. Mice and hamsters immunised with its single dose conferred superior protection against SARS-CoV-2 challenge, “more so than one or two intramuscular immunisations of the same vaccine and dose”.

“Thus, intranasal immunisation of ChAd-SARS-CoV-2-S can create an immune response in the nose, which is the point of entry for the virus, thereby protecting against disease, infection and transmission,” Bharat Biotech said in a statement.

On January 3, two intramuscular vaccines – Bharat Biotech’s Covaxin and Oxford-AstraZeneca’s Covishield manufactured by Serum Institute of India – were approved for restricted emergency use. Both are two-dose vaccines.

While the full efficacy of Covaxin is yet to be determined, it was given go-ahead by the DCGI citing ‘public interest’. Covaxin is an indigenously developed vaccine by Bharat Biotech, in collaboration with the Indian Council of Medical Research (ICMR).

 


Now you can get handpicked stories from Telangana Today onĀ Telegram everyday. Click the link to subscribe.

Click to follow Telangana Today Facebook page and Twitter .

  • Follow Us :
  • Tags
  • Bharat Biotech
  • Covid vaccine trials
  • DCGI
  • DGCI

Related News

  • Country wants Telangana model of development, says BRS MLA Veeraiah

    Country wants Telangana model of development, says BRS MLA Veeraiah

  • Custom-built garages for FIA Formula E cars in Hyderabad

    Custom-built garages for FIA Formula E cars in Hyderabad

  • MYK Strikers make it to quarterfinals of Hyderabad Premier Golf League

    MYK Strikers make it to quarterfinals of Hyderabad Premier Golf League

  • Hyderabad: New basketball court inaugurated at St Andrews School

    Hyderabad: New basketball court inaugurated at St Andrews School

  • India’s first airport drive-in theatre, aqua golf facility at RGIA soon

    India’s first airport drive-in theatre, aqua golf facility at RGIA soon

  • Telangana Govt accords permission for recruitment of 313 Assistant Professors

    Telangana Govt accords permission for recruitment of 313 Assistant Professors

Latest News

  • Pak-linked preacher stopped from attending Warangal event

    10 mins ago
  • Wagon manufacturing facility in Kazipet: Ashwini Vaishnaw

    22 mins ago
  • Former Indian cricketer Bobby shares his journey

    23 mins ago
  • Hanamkonda: Enumamula market committee to clear debts soon

    31 mins ago
  • Hyderabad: Cafe Niloufer re-launches Golden Tips Tea, priced at Rs 1,000

    32 mins ago
  • BRS to hold public meet in Nanded on Sunday

    55 mins ago
  • Hyderabad: 365 persons jailed for drunk driving in January

    59 mins ago
  • Sehra Procession to be held in Hyderabad on Sunday

    1 hour ago

company

  • Home
  • About Us
  • Contact Us

business

  • Subscribe

telangana today

  • Telangana
  • Hyderabad
  • Latest News
  • Entertainment
  • World
  • Andhra Pradesh
  • Science & Tech
  • Sport

follow us

© Copyrights 2022 TELANGANA PUBLICATIONS PVT. LTD. All rights reserved. Powered by Veegam